https://www.nasdaq.com/press-release/aclaris-therapeutics-to-participate-in-the-h.c.-wainwright-bioconnect-virtual
https://www.nasdaq.com/press-release/aclaris-therapeutics-announces-publication-of-preclinical-research-of-zunsemetinib-in
https://www.nasdaq.com/press-release/aclaris-therapeutics-to-host-virtual-rd-day-on-december-7-2021-2021-11-18
https://www.nasdaq.com/press-release/aclaris-therapeutics-to-participate-in-upcoming-investor-conferences-2021-11-03
https://www.nasdaq.com/press-release/aclaris-therapeutics-reports-third-quarter-2021-financial-results-and-provides-a
https://www.nasdaq.com/press-release/aclaris-therapeutics-announces-proposed-settlement-and-settlement-hearing-of
https://www.nasdaq.com/press-release/aclaris-therapeutics-to-participate-in-upcoming-investor-conferences-2021-08-26
https://www.nasdaq.com/press-release/aclaris-therapeutics-reports-second-quarter-2021-financial-results-and-provides-a
https://www.nasdaq.com/press-release/aclaris-therapeutics-to-participate-in-the-william-blair-biotech-focus-conference
https://www.nasdaq.com/press-release/aclaris-announces-pricing-of-public-offering-of-common-stock-2021-06-09
https://www.nasdaq.com/press-release/aclaris-announces-proposed-public-offering-of-common-stock-2021-06-08
https://www.nasdaq.com/press-release/aclaris-therapeutics-announces-positive-preliminary-topline-data-from-phase-2a-trial
https://www.nasdaq.com/press-release/aclaris-therapeutics-to-participate-in-the-jefferies-virtual-healthcare-conference
https://www.nasdaq.com/press-release/aclaris-therapeutics-reports-first-quarter-2021-financial-results-and-provides-a
https://www.nasdaq.com/press-release/aclaris-therapeutics-completes-enrollment-in-its-phase-2a-clinical-trial-of-ati-1777
https://www.nasdaq.com/press-release/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/aclaris-therapeutics-to-participate-in-upcoming-investor-conferences-2021-02-22
https://www.nasdaq.com/press-release/aclaris-therapeutics-to-participate-in-the-10th-annual-svb-leerink-global-healthcare
https://www.nasdaq.com/press-release/aclaris-announces-pricing-of-public-offering-of-common-stock-2021-01-20
https://www.nasdaq.com/press-release/aclaris-announces-proposed-public-offering-of-common-stock-2021-01-19
https://www.nasdaq.com/press-release/aclaris-therapeutics-announces-positive-preliminary-topline-data-from-12-week-phase
https://www.nasdaq.com/press-release/aclaris-therapeutics-announces-formation-of-new-scientific-advisory-board-2020-12-15
https://www.nasdaq.com/press-release/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx
https://www.nasdaq.com/press-release/aclaris-therapeutics-reports-third-quarter-2020-financial-results-and-provides-a
https://www.nasdaq.com/press-release/aclaris-therapeutics-announces-first-patient-dosed-in-phase-2a-clinical-trial-of-ati
https://www.nasdaq.com/press-release/aclaris-therapeutics-to-present-at-upcoming-investor-conferences-2020-09-01
https://www.nasdaq.com/press-release/aclaris-therapeutics-reports-second-quarter-2020-financial-results-and-provides-rd
https://www.nasdaq.com/press-release/aclaris-therapeutics-submits-investigational-new-drug-application-for-ati-1777-a
https://www.nasdaq.com/press-release/aclaris-therapeutics-supports-investigator-initiated-clinical-trial-of-ati-450-for
https://www.nasdaq.com/press-release/aclaris-therapeutics-announces-publication-of-an-abstract-of-the-phase-1-clinical
https://www.nasdaq.com/press-release/aclaris-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference-2020
https://www.nasdaq.com/press-release/aclaris-therapeutics-reports-first-quarter-2020-financial-results-and-provides-rd-and
https://www.nasdaq.com/press-release/aclaris-therapeutics-secures-%2411-million-term-loan-facility-2020-03-31
https://www.nasdaq.com/press-release/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and
https://www.nasdaq.com/press-release/aclaris-therapeutics-to-announce-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/aclaris-therapeutics-to-present-at-the-svb-leerink-9th-annual-global-healthcare
https://www.nasdaq.com/press-release/aclaris-therapeutics-announces-positive-results-from-phase-1-single-and-multiple
https://www.nasdaq.com/press-release/aclaris-therapeutics-announces-appointment-of-vincent-milano-to-board-of-directors
https://www.nasdaq.com/press-release/aclaris-therapeutics-to-present-at-upcoming-investor-conferences-2019-11-12
https://www.nasdaq.com/press-release/aclaris-therapeutics-reports-third-quarter-2019-financial-results-and-provides
https://www.nasdaq.com/press-release/aclaris-therapeutics-to-announce-third-quarter-2019-financial-results-on-november-7
https://www.nasdaq.com/press-release/aclaris-therapeutics-a-101-45-topical-solution-meets-primary-and-all-secondary-0
https://www.nasdaq.com/press-release/aclaris-therapeutics-announces-divestiture-of-rhofader-2019-10-10
https://www.nasdaq.com/press-release/aclaris-therapeutics-files-patent-infringement-lawsuit-against-taro-pharmaceuticals
https://www.nasdaq.com/press-release/shareholder-alert%3a-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-23
https://www.nasdaq.com/press-release/thinking-about-buying-stock-in-aclaris-therapeutics-alder-biopharmaceuticals-capricor
https://www.nasdaq.com/press-release/aclaris-therapeutics-to-hold-rd-day-2019-09-17
https://www.nasdaq.com/press-release/aclaris-therapeutics-a-101-45-topical-solution-meets-primary-and-all-secondary
